Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$10.92 CAD
Change Today +0.31 / 2.92%
Volume 1.3K
COM On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ CM
Frankfurt
As of 3:59 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

cardiome pharma corp (COM) Snapshot

Open
C$10.79
Previous Close
C$10.61
Day High
C$10.95
Day Low
C$10.73
52 Week High
01/21/15 - C$13.80
52 Week Low
08/6/14 - C$6.62
Market Cap
183.2M
Average Volume 10 Days
7.7K
EPS TTM
C$-1.11
Shares Outstanding
16.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CARDIOME PHARMA CORP (COM)

Related News

No related news articles were found.

cardiome pharma corp (COM) Related Businessweek News

No Related Businessweek News Found

cardiome pharma corp (COM) Details

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of cardiovascular therapies that enhance the life and health of patients from heart diseases. It offers BRINAVESS (vernakalant IV) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. It has operations in Canada, the United States, and Europe. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is based in Vancouver, Canada.

Founded in 1986

cardiome pharma corp (COM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$508.3K
Chief Financial Officer
Total Annual Compensation: C$250.2K
Chief Operating Officer
Total Annual Compensation: C$220.3K
Corporate General Counsel
Total Annual Compensation: C$206.0K
Compensation as of Fiscal Year 2013.

cardiome pharma corp (COM) Key Developments

Cardiome Pharma Corp. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Cardiome Pharma Corp. announced consolidated earnings results for the fourth quarter and full year ended December 31, 2014. The company recorded a net loss of $18.2 million (loss of $1.12 per common share) for the year ended December 31, 2014, compared to net earnings of $4.8 million ($0.37 per common share) for the year ended December 31, 2013. Revenue for the year ended December 31, 2014 was $30.0 million, an increase of $25.5 million from $4.5 million for the year ended December 31, 2013 primarily due to sales of AGGRASTAT. Operating loss was $6,424,000 against $7,500,000 a year ago. Loss before income taxes was $6,824,000 against $7,130,000 a year ago. Net cash used in operating activities was $4,037,000 against $5,861,000 a year ago. Purchase of property and equipment was $495,000 against $13,000 a year ago. The company recorded a net loss of $6.5 million or loss of $0.39 per common share for the fourth quarter of 2014, compared to a net loss of $7.2 million or loss of $0.53 per common share for the fourth quarter of 2013. Revenue for the fourth quarter of 2014 was $7.0 million, an increase of $3.1 million from $3.9 million for the fourth quarter of 2013 due primarily to the recognition of a full quarter of AGGRASTAT sales compared to six weeks in the fourth quarter of 2013. Operating loss was $16,585,000 against $16,697,000 a year ago. Loss before income taxes was $18,178,000 against earnings of $4,875,000 a year ago. Net cash used in operating activities was $18,527,000 against $16,768,000 a year ago. Purchase of property and equipment was $522,000 against $39,000 a year ago.

Cardiome Pharma Corp. to Report Q4, 2014 Results on Mar 12, 2015

Cardiome Pharma Corp. announced that they will report Q4, 2014 results at 12:00 PM, GMT Standard Time on Mar 12, 2015

Cardiome Pharma Corp., Q4 2014 Earnings Call, Mar 12, 2015

Cardiome Pharma Corp., Q4 2014 Earnings Call, Mar 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COM:CN C$10.92 CAD +0.31

COM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for COM.
View Industry Companies
 

Industry Analysis

COM

Industry Average

Valuation COM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.8x
Price/Book 8.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDIOME PHARMA CORP, please visit www.cardiome.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.